Treatment options for chronic hepatitis B not responding to interferon

Journal of Hepatology

Volumn 38, Issue 6, 2003, Pages 853-855

  Hadziyannis, Stephanos J ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A;

CANCER RISK; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS RESISTANCE;

EID: 0037564134     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00156-9     Document Type: Editorial

References (23)

1. Hadziyannis SJ, Vassilopoulos D. Hepatitis Be antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120: 1828-53.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41.
4. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003;38(Suppl. 1):S90-S103.
5. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis Be antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
6. Hadziyannis SJ. Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy. J Hepatol 2002; 36:280-2.
7. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-8.
8. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
9. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
10. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:238-43.
11. Cooksley WG, Piratvisuth T, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, et al. Evidence for the efficacy of peginterferon alfa-2a (40 KD) (pegasys) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors. J Hepatol 2002; 36(Suppl. 1):A17.
12. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
13. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
14. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002; 122:2092-3.
15. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:277-82.
16. Janssen HL, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993;17(Suppl. 3):S47-S51.
17. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
18. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
20. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998;28:923-9.
21. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-7.
22. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon non-responders. J Hepatol 2003;38:818-826.
23. Schalm SW. Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence. J Hepatol 2001;35:419-20.